CI vs RNAZ · P/E 2.4, rev $274.90B vs $5.1M cap
Cigna Corp (CI) versus Transcode Therapeutics Inc (RNAZ) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Transcode Therapeutics Inc (RNAZ) is a biotechnology company listed on NASDAQ.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
RNAZ does not have a complete income-statement cache yet.
CI currently screens at market cap $71.62B and trailing P/E 2.4. RNAZ currently screens at market cap $5.1M.
Not investment advice. Open the CI and RNAZ stock pages for the full models.
Not investment advice.